



Rijksinstituut voor Volksgezondheid
en Milieu
*Ministerie van Volksgezondheid,
Welzijn en Sport*

Invasive meningococcal disease in the Netherlands

Mirjam Knol, PhD

National Institute for Public Health and
the Environment (RIVM)



Rijksinstituut voor Volksgezondheid
en Milieu
*Ministerie van Volksgezondheid,
Welzijn en Sport*

Content:

1. Update MenW
2. MenB

Mirjam Knol, PhD

National Institute for Public Health and
the Environment (RIVM)



Disclosure belangen spreker

(potentiële) belangenverstrengeling	Geen
Voor bijeenkomst mogelijk relevante relaties met bedrijven	
<ul style="list-style-type: none">• Sponsoring of onderzoeksgeld• Honorarium of andere (financiële) vergoeding• Aandeelhouder• Andere relatie, namelijk ...	<ul style="list-style-type: none">••••




Surveillance of IMD

- Notifiable disease since 1905
 - Case definition: clinical symptoms and lab confirmation
 - Clinical information including mortality, clinical presentation and vaccination status
- Laboratory surveillance since 1959
 - Netherlands Reference Laboratory for Bacterial Meningitis (AMC/RIVM)
 - Positive CSF or blood isolates or samples (culture and PCR)
 - Serogroup and further subtyping
- Active linkage between notifications and lab data since 2003
- Estimated coverage of >90%






IMD incidence by serogroup



* Up to September




Incidence by serogroup



* Up to September




Incidence by serogroup



* Up to September




MenW 2004-2017



* Up to September




Serogroup distribution



* Up to September




MenW 2015-2017






MenW by age 2015-2017



* Up to September




MenW mortality by age (Oct 2015 – Sep 2017)





Clinical manifestation MenW (Oct 2015 – Sep 2017)





MenACWY vaccination

- 2 vaccines registered in Europe
 - Nimenrix – MenACWY-TT (Pfizer) → 6 weeks of age
 - Menveo – MenACWY-CRM (GSK) → 2 years of age
- September 2017: Decision Minister of Health
 - Based on advice of expert group
 - Replace MenC at 14 months by MenACWY
 - Introduce MenACWY at 12-14 years of age (single birth cohort)
 - › Individual protection
 - › Herd protection through reduction of carriage transmission




Implementation MenACWY vaccination

- When?
 - 2nd quarter of 2018
- Who?
 - Adolescents in the year they will turn 13 or 14 years (birth cohort 2004 or 2005)
 - › Before the peak of disease incidence and carriage
- How?
 - ‘Group’ vaccination
 - Together with HPV?
 - › Limited data on interference (Menveo-Gardasil)
 - ‘No show’ policy
- Why?
 - Communication plan




IMD incidence by serogroup



* Up to September




MenB 2004-2017



* Up to September




MenB by age 2015-2017



* Up to September




MenB and MenW by age 2017 (up to Sept)





MenB mortality by age (2015-2017*)



* Up to September



Summary

- MenW
 - Rapid increase of hypervirulent MenW strain with high mortality
 - Atypical presentation
 - Similarities UK
 - MenACWY vaccine implementation at 14 months and in adolescents starting from 2018
- MenB
 - Stable incidence of MenB with lower mortality
 - In children <5 years still the most dominant serogroup
 - MenB vaccination will be discussed in Health Council in 2018



Acknowledgements

RIVM

- Guy Berbers
- Ingrid Drijfhout
- Laura Kamp
- Hester de Melker
- Nynke Rots
- Helma Ruijs
- Lieke Sanders
- Gerre Vermeulen
- Hans van Vliet

NRLBM

- Arie van der Ende
- Lab personnel

Public Health England

- Ray Borrow
- Helen Campbell
- Steve Gray
- Shamez Ladhani
- Jay Lucidarme
- Mary Ramsay